ABVC BioPharma's subsidiary AiBtl BioPharma Inc. has signed a strategic share-based land acquisition agreement in central Taiwan, valued at $7.67 million. The transaction involves exchanging company shares for exclusive rights to agricultural land designated for cultivating Polygala tenuifolia, a critical botanical ingredient in the company's drug development pipeline.
The land acquisition represents a significant step in AiBtl's strategy to reduce sourcing risks and support large-scale production of active botanical compounds for potential treatments in neurological disorders. By securing upstream agricultural resources, the company aims to create a comprehensive supply chain from cultivation to clinical application.
The targeted land will be used to grow Polygala tenuifolia, which is central to AiBtl's drug candidates for Major Depressive Disorder (MDD) and Attention Deficit Hyperactivity Disorder (ADHD). These markets present substantial opportunities, with the MDD therapeutics market projected to reach $14 billion by 2027 and the ADHD market expected to exceed $24 billion by 2032.
AiBtl's drug candidates offer potential advantages over existing treatments. The MDD candidate promises neuroprotective effects through novel pathways, while the ADHD candidate provides a non-stimulant approach with a strong safety profile. These characteristics are particularly appealing in markets like Asia, where demand for plant-based medical alternatives is growing.
The land acquisition underscores ABVC's long-term commitment to innovative botanical drug development and expanding its operational presence in the Asia-Pacific region. By establishing direct control over raw material sourcing, the company positions itself to potentially accelerate drug development and reduce production uncertainties.
